Unity Biotechnology Files Q1 2025 10-Q
| Field | Detail |
|---|---|
| Company | Unity Biotechnology, Inc. |
| Form Type | 10-Q |
| Filed Date | Apr 22, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotechnology
TL;DR
Unity Bio's Q1 2025 10-Q is in. Check financials & fair value disclosures.
AI Summary
Unity Biotechnology, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported its financial position and operational highlights. Key financial data points and disclosures related to fair value measurements and cash equivalents were included in the filing.
Why It Matters
This filing provides investors with an update on Unity Biotechnology's financial health and operational status as of the first quarter of 2025.
Risk Assessment
Risk Level: medium — As a biotechnology company, Unity Biotechnology faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the financial snapshot date)
- 2025-04-22 — Filing Date (When the report was submitted to the SEC)
Key Players & Entities
- Unity Biotechnology, Inc. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- 20250422 (date) — Date of filing
- South San Francisco, CA (location) — Company's business and mail address
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on April 22, 2025.
What is the company's primary business classification?
The company's Standard Industrial Classification is Pharmaceutical Preparations [2834].
Where is Unity Biotechnology, Inc. located?
Unity Biotechnology, Inc.'s business and mail address is 285 East Grand Avenue, South San Francisco, CA 94080.
What specific financial statement items are mentioned in the filing context?
The filing context mentions items such as Accrued Liabilities Current, Money Market Funds, Restricted Cash Equivalents, Additional Paid In Capital, US Government Agencies Debt Securities, and Cash Equivalents.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on April 22, 2025 regarding Unity Biotechnology, Inc..